Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
BLTE Stock Chart & Stats
$172.76
-$1.45(-2.47%)
At close: 4:00 PM EST
$172.76
-$1.45(-2.47%)
Day’s Range― - ―
52-Week Range$53.60 - $200.00
Previous CloseN/A
Volume15.47K
Average Volume (3M)64.23K
Market Cap
$6.80B
Enterprise Value$6.44B
Total Cash (Recent Filing)$492.42M
Total Debt (Recent Filing)$429.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 19, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding39,965,313
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-103.07
Forecast
1Y Price Target
$215.29Price Target Upside24.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$30.00M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPhase 3 DRAGON topline results showing meaningful slowing of disease progression with favorable tolerability support analyst expectations for strong adoption by retina specialists for eligible patients.
Commercial Strategy And Drug ProfileAn oral once-daily tablet profile combined with management plans to build a targeted sales force and increase genetic testing awareness could accelerate patient identification and uptake versus injectable alternatives.
Regulatory ApprovalRegulatory filing for tinlarebant in Stargardt, backed by multiple expedited and orphan designations, could enable a first-in-class approval and a commercial launch across major markets.
Bears Say
Cash Burn And Financing RiskPlanned substantial spending on research and commercialization may raise cash burn and create the need for additional financing before a commercial launch achieves self-sustaining revenues.
Regulatory Pathway UncertaintyRegulatory uncertainty for Stargardt disease, including the risk that the FDA could request an additional confirmatory trial, could delay U.S. market entry and reduce near-term commercial value.
Valuation RiskRecent strong share appreciation has pushed valuation higher, increasing uncertainty about the magnitude of further upside and making the stock more sensitive to execution setbacks.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $53.59 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $6.80B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is May 19, 2026 which is in 36 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Mar 02, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.166.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.64.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 39,965,313 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went down -6.684%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$215.29 (24.62% Upside)
$215.29 (24.62% Upside)
Hedge Fund Trend
Increased
By 233.8K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
-34.29%
Trailing 12-Months
Asset Growth
143.82%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was positive: the company reported a major clinical milestone (DRAGON Phase III success with 36% lesion-growth reduction), completed strong fundraising and set a clear regulatory and commercial timeline (rolling NDA in Q2 2026; target launch Q1 2027). The company is investing heavily in commercialization and R&D (reflected in sharply higher R&D and SG&A and wider net losses), and there are execution and timing risks around patient identification, pricing, ex-US filings and deprioritized programs. On balance the clinical success and cash runway materially de-risk the near-term path to approval and launch, outweighing the financial burn and execution risks described.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$215.29
▲(24.62% Upside)
Technical Analysis
Denali Therapeutics
―
Kiniksa Pharmaceuticals
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
Ownership Overview
―
Insiders
0.18% Mutual Funds
15.44% Other Institutional Investors
84.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---